Targeted Radionuclide and Fluorescence Dual-modality Imaging of Cancer: Preclinical Advances and Clinical Translation

Molecular Imaging and Biology

Volumn 16, Issue 6, 2014, Pages 747-755

  Lutje S ^a   Rijpkema, M ^a   Helfrich, W ^b   Oyen, W J G ^a   Boerman, O C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cancer; Dual modality imaging; Fluorescence; Radionuclide; Targeting

Indexed keywords

BEVACIZUMAB; CD20 ANTIGEN; CETUXIMAB; ENDOGLIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; FLUORESCENT DYE; FOLIC ACID DERIVATIVE; GASTRIN RELEASING PEPTIDE RECEPTOR; IMMUNOGLOBULIN G1 ANTIBODY; INDOCYANINE GREEN; MALEIMIDE; MATRIX METALLOPROTEINASE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOISOTOPE; SOMATOSTATIN DERIVATIVE; TRASTUZUMAB; VASCULOTROPIN A;

BREAST CANCER; CANCER SURGERY; FLUORESCENCE IMAGING; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; INTRAOPERATIVE PERIOD; MELANOMA; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOSURGERY; REVIEW; SCINTISCANNING; SENTINEL LYMPH NODE BIOPSY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR LOCALIZATION; UTERINE CERVIX CANCER; ANIMAL; CHEMISTRY; DIAGNOSTIC USE; MULTIMODAL IMAGING; NEAR INFRARED SPECTROSCOPY; NEOPLASMS; PATHOLOGY; PROCEDURES;

ANIMALS; FLUORESCENT DYES; HUMANS; MULTIMODAL IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; SPECTROSCOPY, NEAR-INFRARED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84911962735     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-014-0747-y     Document Type: Review

References (53)

1. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90
2. Bristow RE, Puri I, Chi DS (2009) Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 112:265–274
3. Cao C, Yan TD, Black D, Morris DL (2009) A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 16:2152–2165
4. Povoski SP, Neff RL, Mojzisik CM et al (2009) A comprehensive overview of radioguided surgery using gamma detection probe technology. World J Surg Oncol 7:11
5. Vermeeren L, Klop WM, van den Brekel MW et al (2009) Sentinel node detection in head and neck malignancies: innovations in radioguided surgery. J Oncol 2009:681-746
6. Azhdarinia A, Ghosh P, Ghosh S et al (2012) Dual-labeling strategies for nuclear and fluorescence molecular imaging: a review and analysis. Mol Imaging Biol 14:261–276
7. Terwisscha van Scheltinga AG, van Dam GM, Nagengast WB et al (2011) Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med 52:1778–1785
8. Cohen R, Stammes MA, de Roos HC et al (2011) Inert coupling of IRDye800CW to monoclonal antibodies for clinical imaging of tumor targets. EJNMMI Res 1:31
9. Keereweer S, Van Driel PB, Snoeks TJ et al (2013) Optical image-guided cancer surgery: challenges and limitations. Clin Cancer Res 19:3745–3754
10. Somasundaram SK, Chicken DW, Keshtgar MR (2007) Detection of the sentinel lymph node in breast cancer. Br Med Bull 84:117–131
11. van de Lande J, Torrenga B, Raijmakers PG et al (2007) Sentinel lymph node detection in early stage uterine cervix carcinoma: a systematic review. Gynecol Oncol 106:604–613
12. Côté V, Kost K, Payne RJ, Hier MP (2007) Sentinel lymph node biopsy in squamous cell carcinoma of the head and neck: where we stand now, and where we are going. J Otolaryngol 36:344–349
13. Harlow SP, Krag DN, Ashikaga T et al (2001) Gamma probe guided biopsy of the sentinel node in malignant melanoma: a multicentre study. Melanoma Res 11:45–55
14. Fortuin A, Md R, Zamecnik P et al (2013) Molecular and functional imaging for detection of lymph node metastases in prostate cancer. Int J Mol Sci 14:13842–13875
15. Bai M, Bornhop DJ (2012) Recent advances in receptor-targeted fluorescent probes for in vivo cancer imaging. Curr Med Chem 19:4742–4758
16. Patterson MS, Chance B, Wilson BC (1989) Time resolved reflectance and transmittance for the non-invasive measurement of tissue optical properties. Appl Opt 28:2331–2336
17. Fomina N, McFearin CL, Sermsakdi M et al (2011) Low power, biologically benign NIR light triggers polymer disassembly. Macromolecules 44:8590–8597
18. East JM, Valentine CS, Kanchev E, Blake GO (2009) Sentinel lymph node biopsy for breast cancer using methylene blue dye manifests a short learning curve among experienced surgeons: a prospective tabular cumulative sum (CUSUM) analysis. BMC Surg 9:2
19. Kiesslich R, Fritsch J, Holtmann M et al (2003) Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 124:880–888
20. Keereweer S, Kerrebijn JD, van Driel PB et al (2011) Optical image-guided surgery—where do we stand? Mol Imaging Biol 13:199–207
21. Polom K, Murawa D, Rho YS et al (2011) Current trends and emerging future of indocyanine green usage in surgery and oncology: a literature review. Cancer 117:4812–4822
22. van der Poel HG, Buckle T, Brouwer OR et al (2011) Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional imaging approach using a multimodal tracer. Eur Urol 60:826–833
23. van den Berg NS, Valdés-Olmos RA, van der Poel HG, van Leeuwen FW (2013) Sentinel lymph node biopsy for prostate cancer: a hybrid approach. J Nucl Med 54:493–496
24. Schaafsma BE, Verbeek FP, Rietbergen DD et al (2013) Clinical trial of combined radio- and fluorescence-guided sentinel lymph node biopsy in breast cancer. Br J Surg 100:1037–1044
25. Brouwer OR, Klop WM, Buckle T et al (2012) Feasibility of sentinel node biopsy in head and neck melanoma using a hybrid radioactive and fluorescent tracer. Ann Surg Oncol 19:1988–1994
26. 99m)Tc-nanocolloid. Eur J Nucl Med Mol Imaging 39:1128–1136
27. Kelloff GJ, Krohn KA, Larson SM et al (2005) The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 11:7967–7985
28. Luo S, Zhang E, Su Y et al (2011) A review of NIR dyes in cancer targeting and imaging. Biomaterials 32:7127–7138
29. Zhang Y, Hong H, Engle JW et al (2012) Positron emission tomography and near-infrared fluorescence imaging of vascular endothelial growth factor with dual-labeled bevacizumab. Am J Nucl Med Mol Imaging 2:1–13
30. Sampath L, Kwon S, Ke S et al (2007) Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J Nucl Med 48:1501–1510
31. Sampath L, Kwon S, Hall MA et al (2010) Detection of cancer metastases with a dual-labeled near-infrared/positron emission tomography imaging agent. Transl Oncol 3:307–217
32. 89)Zr and IRDye 800CW. Am J Transl Res 4:333–346
33. Hall MA, Kwon S, Robinson H et al (2012) Imaging prostate cancer lymph node metastases with a multimodality contrast agent. Prostate 72:129–146
34. Hall MA, Pinkston KL, Wilganowski N et al (2012) Comparison of mAbs targeting epithelial cell adhesion molecule for the detection of prostate cancer lymph node metastases with multimodal contrast agents: quantitative small-animal PET/CT and NIRF. J Nucl Med 53:1427–1437
35. Banerjee SR, Pullambhatla M, Byun Y et al (2011) Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. Angew Chem Int Ed Engl 50:9167–9170
36. Azhdarinia A, Wilganowski N, Robinson H et al (2011) Characterization of chemical, radiochemical and optical properties of a dual-labeled MMP-9 targeting peptide. Bioorg Med Chem 19:3769–3776
37. Huang M, Xiong C, Lu W et al (2014) Dual-modality micro-positron emission tomography/computed tomography and near-infrared fluorescence imaging of EphB4 in orthotopic glioblastoma xenograft models. Mol Imaging Biol 16:74–84
38. Meadows KL, Hurwitz HI (2012) Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med 2(10). doi:10.1101/cshperspect.a006577
39. Yarden Y (2011) Biology of HER2 and its importance in breast cancer. Oncology 61(Suppl 2):1–13
40. Ogawa M, Regino CA, Seidel J et al (2009) Dual-modality molecular imaging using antibodies labeled with activatable fluorescence and a radionuclide for specific and quantitative targeted cancer detection. Bioconjug Chem 20:2177–2184
41. Faybik P, Hetz H (2006) Plasma disappearance rate of indocyanine green in liver dysfunction. Transplant Proc 38:801–802
42. Fonsatti E, Nicolay HJ, Altomonte M et al (2010) Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res 86:12–19
43. Dallas NA, Samuel S, Xia L et al (2008) Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res 14:1931–1937
44. Seon BK, Haba A, Matsuno F et al (2011) Endoglin-targeted cancer therapy. Curr Drug Deliv 8:135–143
45. 89)Zr and IRDye 800CW. Mol Pharm 9:2339–2349
46. Zhang Y, Hong H, Nayak TR et al (2013) Imaging tumor angiogenesis in breast cancer experimental lung metastasis with positron emission tomography, near-infrared fluorescence, and bioluminescence. Angiogenesis 16:663–674
47. Went P, Vasei M, Bubendorf L et al (2006) Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 94:128–135
48. Schülke N, Varlamova OA, Donovan GP et al (2003) The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci U S A 100:12590–12595
49. 18F]FPy-DUPA-Pep). Appl Radiat Isot 69:1014–1018
50. Silver DA, Pellicer I, Fair WR et al (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81–85
51. Lütje S, Rijpkema M, Franssen GM et al (2014) Dual-modality image-guided surgery of prostate cancer with a radiolabeled fluorescent anti-PSMA monoclonal antibody. J Nucl Med. doi:10.2967/jnumed.114.138180
52. Paudyal P, Paudyal B, Iida Y et al (2009) Dual functional molecular imaging probe targeting CD20 with PET and optical imaging. Oncol Rep 22:115–119
53. van Dam GM, Themelis G, Crane LM et al (2011) Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med 17:1315–1319